The advancement of technologies to generate monoclonal antibodies (MAbs) creates considerable excitement in oncology because of their potential use in cancer therapy. The application of agonistic/antagonistic mAbs against certain targets has emerged as one of the most effective ways to boost immune responses against infectious agents or to fight malignant tumors. As a first-class biological company around the world, Creative Biolabs is specialized in new agonistic & antagonistic antibody discovery, development, and therapeutic practices.Fig.1 Anti-4-1BB agonistic antibody. (Compte, 2018)
The function of immune cells is regulated by co-stimulatory and co-inhibitory receptors. It is known that the first two generations of cancer immunotherapy agents are primarily composed by antagonist antibodies that dampen negative immune checkpoints, for example, programmed cell death protein 1 (PD1)/PD-ligand 1 (PD-L1) and cytotoxic T lymphocyte protein 4 (CTLA4). Looking into the future, there is considerable promise in targeting co-stimulatory receptors with agonist antibodies, and a large number of these drug agents are making their way through different stages of development. The differentiating features and potential efficacies describe the landscape of both antibodies in clinical use for cancer treatment. Thus, scientists pay close attention to the critical considerations and underlying deficiencies of immune agonist/antagonist antibody design in order to generate much safer and cost-effective products.
Receptor agonism is a key step in the transmission of signals from the outside to the inside of a cell. The agonist activity can occur when the antibody binds the receptor in a manner that mimics the binding of the natural ligand, resulting in antibody-mediated downstream signaling or agonism. Antibody-mediated agonist activity can occur when the two FAb arms of an IgG each bind to a halfreceptor of a homodimeric receptor pair and cause the receptors to dimerize, or cross-link, in a way that mimics the activity of the natural ligand. There are currently at least 11 mAbs in clinical trials that are intended to function as receptor agonists. Conversely, a receptor antagonist is a kind of drug that inhibits an immune response by binding to and blocking a receptor rather than activating it like an agonist.
At Creative Biolabs, we review the current understanding of agonist/antagonist antibodies that target immune checkpoints in cancer, highlighting the therapeutic promise and critical needs relevant to this class of agents. Our experts focus on the mechanisms of how therapeutic antibodies interact with their target receptors and devote to address the unique challenges in the design and development of these immune agonistic or antagonistic therapies. Here, we’d like to produce high-quality antibodies that are different from those used for first-generation immune checkpoint agonists/antagonists. There is a summary of our outstanding platforms and combination approaches in which these agents are being developed for the treatment of cancers or various diseases. Our characteristic services regarding agonistic antibodies include but not limited to:
And our popular services regarding antagonistic antibodies include but not limited to:
Agonist/antagonist antibodies are derived from the immune system’s adaptive arm to defend the organism from foreign pathogens and malignant cells. There is no doubt that these antibodies function to promote health and the treatments based on them might be extraordinarily curative. With an impressive performance in the antibody market, Creative Biolabs has successfully isolated and developed a series of immune agonistic/antagonistic antibodies to a panel of receptors, including the tumor necrosis factor (TNF) receptor superfamily, CD137 (4-1BB), CD134 (OX40), CD27, CD28, CD40, PD1/PD-L1 and so on. For more information, please feel free to contact us.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.